8-Hydroxyquinoline
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
Title
See full prescribing information for complete Boxed Warning.
ConditionName:
|
Overview
8-Hydroxyquinoline is a that is FDA approved for the {{{indicationType}}} of *Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.
- Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures.. There is a Black Box Warning for this drug as shown here. Common adverse reactions include .
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition1
- Indium In 111 oxyquinoline is indicated for radiolabeling autologous leukocytes.
- Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process.
- Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. Ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. If localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. If localization or diagnosis by these methods fails or is ambiguous, indium In 111 oxyquinoline labeled leukocyte imaging may be appropriate.
Dosing Information
- The recommended adult (70 kg) dose of indium In 111 oxyquinoline labeled autologous leukocytes is 7.4 to 18.5 MBq, 200-500 µCi. Indium In 111 oxyquinoline solution is intended for the radiolabeling of autologous leukocytes. The indium In 111 oxyquinoline labeled autologous leukocytes are administered intravenously.
- Imaging is recommended at approximately 24 hours post injection. Typically, anterior and posterior views of the chest, abdomen and pelvis should be obtained with other views as required.
- Aseptic procedures and a shielded syringe should be employed in the withdrawal of indium In 111 oxyquinoline from the vial. Similar procedures should be employed during the labeling procedure and the administration of the labeled leukocytes to the patient. The user should wear waterproof gloves during the entire procedure. The patient's dose should be measured by a suitable radioactivity calibration system immediately before administration. At this time, the leukocyte preparation should be checked for gross clumping and red blood cell contamination.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of 8-Hydroxyquinoline in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of 8-Hydroxyquinoline in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of 8-Hydroxyquinoline in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of 8-Hydroxyquinoline in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of 8-Hydroxyquinoline in pediatric patients.
Contraindications
- Condition1
Warnings
Title
See full prescribing information for complete Boxed Warning.
ConditionName:
|
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of 8-Hydroxyquinoline in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of 8-Hydroxyquinoline in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of 8-Hydroxyquinoline in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of 8-Hydroxyquinoline during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of 8-Hydroxyquinoline with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of 8-Hydroxyquinoline with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of 8-Hydroxyquinoline with respect to geriatric patients.
Gender
There is no FDA guidance on the use of 8-Hydroxyquinoline with respect to specific gender populations.
Race
There is no FDA guidance on the use of 8-Hydroxyquinoline with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of 8-Hydroxyquinoline in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of 8-Hydroxyquinoline in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of 8-Hydroxyquinoline in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of 8-Hydroxyquinoline in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of 8-Hydroxyquinoline in the drug label.
- Description
IV Compatibility
There is limited information regarding IV Compatibility of 8-Hydroxyquinoline in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of 8-Hydroxyquinoline in the drug label.
Pharmacology
There is limited information regarding 8-Hydroxyquinoline Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of 8-Hydroxyquinoline in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of 8-Hydroxyquinoline in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of 8-Hydroxyquinoline in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of 8-Hydroxyquinoline in the drug label.
How Supplied
Storage
There is limited information regarding 8-Hydroxyquinoline Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::8-Hydroxyquinoline |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::8-Hydroxyquinoline |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of 8-Hydroxyquinoline in the drug label.
Precautions with Alcohol
- Alcohol-8-Hydroxyquinoline interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- ®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ Empty citation (help)
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=8-Hydroxyquinoline |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=8-Hydroxyquinoline |Label Name=8-Hydroxyquinoline11.png
}}
{{#subobject:
|Label Page=8-Hydroxyquinoline |Label Name=8-Hydroxyquinoline11.png
}}